TL;DR
Get beauty and skincare favorites delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Amorepacific Ventures has made a strategic investment in biotechnology company Junevity, alongside a licensing agreement covering cosmetic applications. The companies plan to use Junevity’s RESET Platform to investigate skin-ageing pathways; Amorepacific will lead any cosmetic product development and commercialisation. No products, launch dates or investment amount were disclosed in the report.
Amorepacific Ventures, the corporate investment arm of the South Korean beauty company behind Laneige, has invested in biotechnology firm Junevity and signed a separate licensing agreement for cosmetic applications. The partnership will use Junevity’s RESET Platform to explore skin-ageing pathways that could inform future cosmetics, with Amorepacific responsible for product development and commercialisation.
The companies said their joint work will pair Junevity’s target-discovery platform with Amorepacific’s expertise in skin biology, cosmetic research and product development. Their stated aim is to identify pathways that may be suitable for cosmetic use, including approaches intended to reset or rejuvenate skin gene networks toward a healthier state. These are research goals, not evidence that a product or skin benefit has already been demonstrated.
Under the arrangement, Amorepacific will lead cosmetic development and commercialisation. Junevity will continue to advance therapeutic applications of its platform separately from the cosmetic collaboration. The source report describes an investment and licensing agreement but gives no financial terms, license scope, development timetable or specific candidate ingredients.
Amorepacific R&I Center CTO Brian Byung-Fhy Suh said the work would examine the biology of skin ageing, including gene networks and transcriptional regulation. Junevity co-founder and CEO John Hoekman said the collaboration could extend the platform into skin care and other markets. Those statements describe the companies’ rationale and expectations; neither establishes the effectiveness of future cosmetic products.
A Biotech Route Into Skin Care
The agreement brings a biotechnology platform focused on biological target discovery into a consumer cosmetics company’s research and product pipeline. For Amorepacific, the partnership may provide a way to investigate skin ageing at the level of gene networks, while Junevity gains a commercial partner with skin-science and cosmetics development capabilities. The structure separates the two companies’ roles: Junevity supplies platform research, and Amorepacific leads cosmetic applications.
The development is relevant to consumers because it signals interest in using biological research to shape future skin-care products. It does not, however, mean a new treatment is available or that the proposed approach has been shown to reverse skin ageing. Cosmetic claims, ingredients, evidence and timelines will depend on research and product development that have not yet been detailed. The source report does not identify any planned launch or consumer-facing product.
As an affiliate, we earn on qualifying purchases.
From Platform Research to Cosmetics
Amorepacific is the parent company of skin-care brand Laneige and operates a corporate venture arm, Amorepacific Ventures. The reported deal combines a strategic investment with a separate licensing agreement for applications in the cosmetics field. The source does not state whether the investment gives Amorepacific a particular ownership share or disclose other financial arrangements.
Junevity’s RESET Platform is described as a system for discovering biological targets and pathways. In this collaboration, the companies intend to apply that research to skin ageing, while Junevity continues to pursue therapeutic uses of the technology. Hoekman also referred to Junevity’s lead siRNA candidate for obesity, which he said was headed toward human clinical trials. That separate therapeutic program is not the subject of the cosmetics agreement and does not establish the status or prospects of the skin-care research.
““The next-generation of skin health innovations will be informed by deeper research-driven insights into the biology of skin ageing, particularly the role of gene networks and transcriptional regulation in longevity.””
— Brian Byung-Fhy Suh, CTO of Amorepacific R&I Center
Product Plans Remain Undisclosed
The companies have not disclosed the investment amount, licensing terms, research milestones or expected development schedule. It is also unclear which specific pathways or cosmetic concepts will be investigated first, what evidence would be required to move a concept toward a product, or when consumers might see any result.
The announcement reports an intention to explore biological mechanisms; it does not report completed studies, validated cosmetic benefits or a product launch. The meaning of “reset” and “rejuvenate” in the companies’ research description is not defined in the source, and no claims about the performance of a future product can be assessed from the information provided.
Research Will Define the Next Steps
The immediate next step is the companies’ joint research into skin-ageing pathways using Junevity’s RESET Platform and Amorepacific’s skin-biology expertise. Amorepacific is expected to lead any cosmetic development and commercialisation arising from the work, while Junevity continues its therapeutic programs. The source does not name a research milestone or date for an update.
Further details to watch for include the targets selected for cosmetic applications, evidence from research, the scope of the license and any decision to develop a specific product. Until the companies disclose such developments, the announcement represents a research and commercial partnership rather than a confirmed new skin-care product.
Key Questions
What did Amorepacific announce?
Amorepacific Ventures invested in Junevity and entered a separate licensing agreement for cosmetic applications. The companies plan to investigate skin-ageing pathways using Junevity’s RESET Platform.
What is Junevity’s RESET Platform intended to do in this partnership?
The platform will be used to discover biological targets and pathways that may be relevant to cosmetic research on skin ageing. The report does not describe a completed skin-care product or established benefit from this work.
Who would develop and sell any resulting cosmetics?
Amorepacific will lead cosmetic product development and commercialisation, according to the report. Junevity will continue advancing therapeutic applications of its platform.
When will a product be available?
No product launch date or development timetable was disclosed. The companies have described research plans, not a product ready for sale.
How much did Amorepacific invest?
The source report does not give the investment amount or other financial terms.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
